Venus Medtech (Hangzhou), Inc. provides transcatheter heart valve medical device. The company is headquartered in Hangzhou, Zhejiang and currently employs 560 full-time employees. The company went IPO on 2019-12-10. The firm focuses on the field of structural heart disease. The firm's products include a series of interventional devices for heart valve diseases, such as transcatheter aortic valve replacement (TAVR), transcatheter pulmonary valve replacement (TPVR), transcatheter mitral valve replacement (TMVR), and transcatheter tricuspid valve replacement (TTVR), as well as surgical consumables. The firm distributes its products within the domestic market and to overseas markets.